InvestorsHub Logo

H2R

Followers 41
Posts 2215
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: None

Thursday, 04/28/2022 11:33:13 AM

Thursday, April 28, 2022 11:33:13 AM

Post# of 43835
ASCO Abstract: Leukocyte interleukin injection (LI) immunotherapy extends overall survival (OS) in treatment-naive low-risk (LR) locally advanced primary squamous cell carcinoma of the head and neck: The IT-MATTERS study.

See: https://meetings.asco.org/abstracts-presentations/207201
Author: Eyal Talor PhD
See: https://cel-sci.com/management-team/#eyal

Best of luck with your investments!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News